Pfizer Moves To Block Unichem Over Xeljanz Patent
This article was originally published in Scrip
Pfizer has moved court against Unichem Laboratories seeking to block the Indian firm from allegedly infringing its patents concerning the rheumatoid arthritis therapy, tofacitinib (Xeljanz).
You may also be interested in...
Indian companies have cried foul over what they claim are "unethical" practices deployed by foreign firms in the legal arena, among others, to safeguard their "patent monopoly".
Astellas inks agreement with Dyno Therapeutics for access to its CapsidMap platform for novel AAV vectors. Taiho takes option to Arcus TIGIT-targeted antibody candidates.
To ensure the Beijing Winter Olympics is a smooth affair, the Chinese government has ordered partial or complete halts in industrial production in some provinces from late November until mid-March, disrupting an already fragile global pharma active ingredient supply chain. The emergence of the Omicron coronavirus variant is just adding to the complexities.